Shenzhen Simeiquan Biotechnology

Shenzhen Simeiquan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, focused on the discovery and development of innovative small molecule therapeutics. Established in 2016, the company primarily targets oncology and other serious diseases with high unmet medical needs. Its lead candidate, SMQ-001, is a novel small molecule inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Simeiquan leverages an integrated drug discovery platform to optimize the potency and selectivity of its pipeline candidates. The company aims to provide affordable and effective precision medicines to patients globally. It is located in the Pingshan District, a major biotechnology hub in the region.